Press Releases

EndoBarrier® Study in Morbidly Obese Adolescents Completes Enrollment

First study of EndoBarrier in adolescents completed at University Children’s Hospital (UCH) in Ljubljana, Slovenia Preliminary data show BMI reduced by 10 percent Acceptable safety profile and improvement in metabolic parameters BOSTON and SYDNEY — 16 February 2017 — GI Dynamics, Inc. (ASX:GID), a...

read more

GI Dynamics, Inc. Provides 2017 Business Outlook and 2016 Review

BOSTON and SYDNEY — 11 January 2017 — GI Dynamics, Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe for patients with type 2 diabetes and obesity, today released a 2017 business outlook and recap of 2016 accomplishments. 2017 marks the first full calendar...

read more

EndoBarrier® Makes Advancement Toward German Reimbursement

EndoBarrier® Makes Advancement Toward German Reimbursement GI Dynamics®, Inc. (ASX: GID), a medical technology company that has developed an innovative device to improve outcomes for patients with type 2 diabetes and obesity, continues to make progress toward full reimbursement in Germany. Germany...

read more

German Registry Releases Positive EndoBarrier Data at EASD

German Registry Releases Positive EndoBarrier Data at EASD BOSTON, Massachusetts, United States, and SYDNEY, Australia – November 9, 2016, AEDT Mean reduction in absolute HbA1c of 1.3% Insulin usage dropped 42% GLP-1 usage reduced in 78% of patients Excess weight loss of 15kg, or 29% of excess...

read more

TGA Cancellation of EndoBarrier Listing

TGA Cancellation of EndoBarrier Listing GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical technology company that has developed an innovative device to improve outcomes for patients diagnosed with type 2 diabetes and obesity, has received final cancellation notification from the...

read more

Appendix 4C: Quarter ended 30 June 2016

Appendix 4C: Quarter ended 30 June 2016 GI Dynamics, Inc. (ASX: GID) (the Company), a medical technology company that has developed an innovative device to improve outcomes for patients battling type 2 diabetes and obesity, today released its Appendix 4C — Quarterly Cash Flow Report for the...

read more

Final Efficacy and Safety Results of U.S. ENDO Trial Announced at ADA

Final Efficacy and Safety Results of U.S. ENDO Trial Announced at ADA Statistically and clinically significant efficacy: 1.1% absolute reduction in HbA1c Statistically and clinically significant efficacy: 7.7% reduction in body weight 34.8% of patients achieved the ADA target of HbA1c ≤ 7.0% after...

read more
Page 1 of 3123

Filter By Year